AIM Vaccine Forecasts Surge in Stock Performance: Innovations Reinforce Leadership in Vaccine Sector
HONG KONG, Aug. 28, 2025 /PRNewswire/ -- AIM Vaccine (06660.HK), a leading domestic vaccine company, announced today the release of its 2025 interim report, showcasing robust revenue growth. With major products entering the market phase, R&D costs are decreasing, and operational expenditures are ...
AIM Vaccine's Next-Gen mRNA Shingles Vaccine Secures Clinical Approvals in Both PRC and U.S. ,mRNA Platform Advantages Shine Through
HONG KONG, May 19, 2025 /PRNewswire/ -- While global giants like Moderna and BioNTech apply mRNA technology to broader disease markets, PRC's mRNA frontrunner is keeping pace. AIM Vaccine (06660.HK), a leading domestic vaccine company, announced today that its self-developed mRNA shingles vaccine...
AIM's Serum-Free Iterative Rabies Vaccine Receives Acceptance for Market Registration; Institutions Predict Significant Valuation Recovery Potential for the Company
HONG KONG, April 8, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, announced onApril 7, 2025 that the company's research and development of the serum-free iterative rabies vaccine has received an "Acceptance Notice" from the National Medical Products Admini...
AIM Vaccine reduces losses by nearly 90% in 2024, with the iterative major product series opening up space for explosive growth in performance
HONG KONG, March 31, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published its 2024 Annual Results announcement on March 30, 2025, the company recorded revenues of RMB 1,285 million in 2024, an increase of 8.2% compared to the previous year, with significa...
AIM Vaccine's mRNA Shingles Vaccine Approved by the US FDA to Begin Clinical Trials, AI-Enabled mRNA Major Vaccine Product Development Accelerates
HONG KONG, March 24, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement onMarch 23, 2025, the company's independently developed mRNA shingles vaccine has recently received clinical trial approval from the U.S. Food and Drug Administrati...
AIM Vaccine reported a significant reduction in losses for 2024, with several major products set to launch that are expected to drive substantial revenue growth
HONG KONG, March 17, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement onMarch 17, 2025, the company's performance in 2024 showed a significant reduction in losses. Preliminary assessments indicate that the company's revenue is expecte...
AIM Vaccine's Serum-Free Iterative Rabies Vaccine Has Received Production License and Will Submit for Market Registration
Launch of Major Product Expected to Significantly Drive Performance Growth HONG KONG, March 12, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement onMarch 12, 2025, the company's serum-free iterative rabies vaccine has recently obtained...
AIM Vaccine's Iteratively Upgraded Diploid Rabies Vaccine Approved for Clinical Trials, Showing Significantly Higher Efficacy than Marketed Diploid Rabies Vaccines
HONG KONG, March 10, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement onMarch 9, 2025, the company's research and development of a diploid rabies vaccine has recently received the Clinical Trial Approval Notice from the National Medic...
AIM Vaccine's mRNA RSV Vaccine Approved for U.S. Clinical Trials
Innovation and Global Expansion Attract Capital Reassessment AIM Vaccine Co., Ltd. (a joint stock company incorporated in the People's Republic of China with limited liability) (Stock Code: 6660.HK) HONG KONG, Feb. 27, 2025 /PRNewswire/ -- The stocks in the Hong Kong pharmaceutical sector have ...
AIM Vaccine's mRNA Shingles Vaccine Submits Clinical Application to the U.S.
Another Step Forward in Global Expansion HONG KONG, Feb. 25, 2025 /PRNewswire/ -- As global capital reassesses the investment value of innovative Chinese companies, the development of innovative vaccines inChina is in full swing. On February 23, PRC vaccine leader AIM Vaccine (06660.HK) announce...
AIM Vaccine Integrates DeepSeek: Innovative Technology and Growth Potential Support Valuation Upside
HONG KONG, Feb. 24, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement onFebruary 23, 2025, announced that the company is fully deploying the DeepSeek large model and promoting the application of DeepSeek R1 version across all business ...
AIM Vaccine Leverages AI to Advance mRNA Vaccine Development mRNA Shingles Vaccine Submits Clinical Trial Application
HONG KONG, Feb. 12, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement onFebruary 11, 2025, announced that its independently developed mRNA shingles vaccine has been submitted for clinical trials to the Center for Drug Evaluation (CDE) ...
